Unity Biotechnology News

UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases

GlobeNewswireApr 25 08:00 ET

UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME

PDF Version SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or r

Unity BiotechnologyApr 23 20:00 ET

Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment

Unity Biotechnology (UBX) early Tuesday said phase 2b testing of its UBX1325 drug candidate has been extended by an extra 12 weeks allowing researchers to compare the drug's durability with aflibercep

MT NewswiresApr 23 10:37 ET

Express News | UNITY Biotechnology : Believe That Current Cash, Cash Equivalents and Marketable Securities Are Sufficient to Fund Operations Into Q3 of 2025

Moomoo 24/7Apr 23 08:03 ET

Express News | UNITY Biotechnology Announces Extension Of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 For Patients In Diabetic Macular Edema

Moomoo 24/7Apr 23 08:02 ET

Express News | UNITY Biotechnology Inc: Expects to Disclose Topline Results From Aspire Study in Two Data Readouts: 24-Week Primary Endpoint Data in Q1 of 2025

Moomoo 24/7Apr 23 08:02 ET

Express News | UNITY Biotechnology Inc: Phase 2B Aspire Study of Ubx1325 Is Being Upsized From 40 to 50 Patients to Increase Statistical Power

Moomoo 24/7Apr 23 08:02 ET

Express News | UNITY Biotechnology Inc: Ongoing Phase 2B Aspire Study of Ubx1325 Has Been Extended From 24 to 36 Weeks

Moomoo 24/7Apr 23 08:01 ET

Express News | UNITY Biotechnology Announces Extension of Phase 2B Aspire Clinical Study Evaluating Ubx1325 in Dme

Moomoo 24/7Apr 23 08:00 ET

Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwri

BenzingaApr 17 08:21 ET

Unity Biotechnology Is Maintained at Buy by HC Wainwright & Co.

Unity Biotechnology Is Maintained at Buy by HC Wainwright & Co.

Dow JonesApr 16 07:15 ET

Express News | HC Wainwright & Co. Maintains Buy on Unity Biotechnology, Lowers Price Target to $8

Moomoo 24/7Apr 16 07:05 ET

Unity Biotechnology Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 419.48% HC Wainwright & Co. $10 → $8 Maintains Buy 11/16/2023 — Wedbush Upgrades Neutral → Out

BenzingaApr 16 07:02 ET

Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)

TipRanksApr 16 06:31 ET

Express News | UNITY Biotechnology Inc : H.c. Wainwright Cuts Target Price to $8 From $10

Moomoo 24/7Apr 16 06:09 ET

Express News | Unity Biotechnology's 2023 Cash, Cash Equivalents And Marketable Securities Of $43.2M Is Expected To Fund Operations Into Q3 Of 2025

Moomoo 24/7Apr 15 07:23 ET

Express News | Unity Biotechnology Q4 2023 GAAP EPS $(0.28) May Not Be Comparable To $(0.77) Estimate

Moomoo 24/7Apr 15 07:22 ET

Unity Biotechnology GAAP EPS of -$0.28 Beats by $0.49

Seeking AlphaApr 15 07:10 ET

Express News | UNITY Biotechnology Inc - Qtrly Shr Loss $0.28

Moomoo 24/7Apr 15 07:01 ET

Express News | UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Moomoo 24/7Apr 15 07:00 ET